Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Epidemiology, Health Policy, and Outcomes

Poster Session C

Session: (1877–1913) Epidemiology & Public Health Poster III

1883: Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1

    Abstract Poster Presenter(s)

  • BB

    Bogdan Batko, MD

    UAFM
    Cracow, Poland

    Disclosure information not submitted.


Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To examine the temporal relationship between psoriatic arthritis (PsA) and cardiometabolic disorders by comparing their prevalence patterns before and after PsA diagnosis.

Methods: This nationwide retrospective case-control study analyzed Polish National Health Fund claims data (2011–2021). We identified 3,391 incident PsA patients diagnosed in 2016 using a definition requiring either: ICD-10 codes (M07.0-M07.3, L40.5) plus DMARD prescriptions, or ≥3 encounters with these codes in rheumatology settings. Cases were matched 1:10 to population controls by age, sex, and region. Cardiometabolic conditions (including hypertension, diabetes, ischemic heart disease, and metabolic disorders) were assessed based on ≥2 recorded diagnoses during five-year periods before and after PsA diagnosis.

Results: PsA patients demonstrated significantly elevated cardiometabolic risk both before and after diagnosis. Prevalence ratios (PR) were consistently higher across multiple conditions, with slight increases observed following diagnosis: hypertensive diseases (pre-PR 1.05 [95% CI 1.03–1.06] to post-PR 1.06 [1.04–1.07]), diabetes mellitus (pre-PR 1.05 [1.03–1.07] to post-PR 1.06 [1.04–1.08]), and ischemic heart diseases (pre-PR 1.04 [1.02–1.06] to post-PR 1.05 [1.03–1.07]). Notably, obesity showed the highest relative risk (pre-PR 1.13 [1.04–1.24] to post-PR 1.20 [1.09–1.32]). The mean cardiometabolic burden per patient increased by 34% following PsA diagnosis (from 0.32 to 0.43 conditions), with marked increases in heart failure (154%), lipoprotein disorders (50%), and diabetes (46%).

Conclusion: Temporal patterns in comorbidity of cardiovascular significance support the concept of shared inflammatory and metabolic pathways underlying these associations, highlighting the need for early cardiometabolic risk assessment and intervention in PsA management.